title: [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
authors.forename: Su
authors.initials: S
authors.lastname: Gao
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: Hu
authors.forename: Hui-ying
authors.initials: HY
authors.lastname: Qiu
authors.forename: Yang
authors.initials: Y
authors.lastname: Xu
authors.forename: Zheng-ming
authors.initials: ZM
authors.lastname: Jin
authors.forename: Guang-sheng
authors.initials: GS
authors.lastname: He
authors.forename: Xiao-wen
authors.initials: XW
authors.lastname: Tang
authors.forename: Yue
authors.initials: Y
authors.lastname: Han
authors.forename: Su-ning
authors.initials: SN
authors.lastname: Chen
authors.forename: Ai-ning
authors.initials: AN
authors.lastname: Sun
authors.forename: De-pei
authors.initials: DP
authors.lastname: Wu
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D001374:Azacitidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077209:Decitabine; D005260:Female; D006801:Humans; D059785:Karyotype; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D000077209:Decitabine; D001374:Azacitidine